Michael demicco md cv

CURRICULUM VITAE
Michael P. DeMicco, M.D., F.A.C.G., A.B.A.M.
8534 Phoenix Avenue
Fountain Valley, CA 92708
714.270.7036 Cell, 714.778.1300 Office
[email protected]
www.michaelpdemiccomd.com
PERSONAL INFORMATION
Born: Bronx, New York
Reside in: Orange County, California since 1975
Married, Two Children
SPECIALTY
Dr. Michael DeMicco is a board certified gastroenterologist with a specialty in hepatitis,
pancreatitis, biliary diseases, colon problems and addiction. Dr. DeMicco is board certified as
well in internal medicine and addictionology. He is highly skilled in all endoscopic procedures
including ERCP, colonoscopy, and upper endoscopy. He has performed over 40,000 procedures
in the last 30 years. He is the Director of Liver Studies for AGMG as well as the Director of the
GI Lab. Dr. Michael DeMicco attended Colgate University and then University Medical School
in Brooklyn. He did his internship in internal medicine at Nassau County Medical Center in
Long Island, New York. He did his internal medicine residency in the public health service. Dr.
DeMicco has served as a Lieutenant Third Grade in the U.S. Public Health Service for six years.
EDUCATION
Internship
1971-1972 Nassau County Medical Center, East Meadow, New York 1967-1971 State University of New York Downstate Medical Center, Bachelor of Science 1963-1967 Colgate University, Hamilton, NY, Bachelor of Arts-Biology POSTDOCTORAL TRAINING
Residency
1972-1975 U.S.P.H.S. Hospital Staten Island, Staten Island, New York FELLOWSHIP
Fellowship
1975-1977 University of California Irvine, Orange County, CA SPECIMEN
LICENSURE
Medical License:
CERTIFICATION
1975
Pan American Medical Association, Board of Alcoholism Committee American Board of AddictionologyAmerican Medical Society of Alcoholism and Other Drug Dependencies ACADEMIC APPOINTMENTS
1993
HOSPITAL APPOINTMENTS
1996 to Present
Chapman Medical Center Associate Medical Director, Positive Action Anaheim Memorial Member, Hyperlimentation CommitteeMedical Center Member Gastroenterology Committee Member Special Task Force STAFF AFFILIATIONS
Anaheim Memorial Medical Center
Chapmen Medical Center
Irvine Medical Center
Placentia-Linda Hospital
St. Jude Hospital- Fullerton
Western Medical Center – Anaheim
Western Medical Center – Santa Ana
Tustin Medical Center
PRIVATE PRACTICE
1977 to present
Associated Gastroenterology Medical Group1211 W. LaPalma Avenue, #303Anaheim, CA 92801Phone: 714.778-1300Fax: 714.778.0667 OTHER PROFESSIONAL POSITIONS AND MAJOR VISTING APPOINTMENTS
AGMG Clinical Research1211 W. La Palma Ave., #303Anaheim, California 92801Phone: 714.778.1300Fax: 714.778.0667 AGMG Clinical Research2617 E. Chapman Avenue, #302Orange, California 92869Phone: 714.633.1823 SPECIMEN
Los Angeles Rams Professional Football TeamConsulting Team Physician Advanced Clinical Research Institute1085 N. Harbor Blvd.
Anaheim, California 92801 Advanced Clinical Research Institute1211 W. La Palma Ave., #303Anaheim, California 92801 AGMG Endoscopy CenterMedical Director1211 W. La Palma Avenue, #301Anaheim, California 92801Phone: 714,284.0737Fax: 714.284.0720 Associated Gastroenterology Medical Group2617 E. Chapman Avenue, #302Orange, California 92869Phone: 714.633.1823Fax: 714.633.1615 Associated Gastroenterology Medical Group1211 W. LaPalma Avenue, #303Anaheim, CA 92801Phone: 714.778-1300Fax: 714.778.6235 PRINCIPAL CLINICAL HOSPITAL RESPONSIBILITES AND PROFESSIONAL
ACTIVITIES
Director of GI Labs at
Director of Adolescent Drug and Alcohol Programs at Western Medical Center Anaheim 1994to 1998Director of Adolescent Drug and Alcohol Programs Anaheim Memorial Hospital 2000 to 2002Associate Director of Adult and Adolescent Drug and Alcohol Programs at Chapman Hospital1994 to 2011 AWARDS AND HONORS
Mentor for NA’s, PA’s and medical students since 1975
Bockus Fellow
COMMITTEE ASSIGNMENTS
Hyperalimentation Committee
SPECIMEN
MEMBERSHIPS
American Medical Society on Alcoholism
American Society for Parenteral and Enteral Nutrition
American Society for Gastrointestinal Endoscopy
California Medical Association
Orange County Gastroenterology Society
Orange County Medical Association
Pan American Medical Association - Council on Alcoholism
Chronic Liver Disease Foundation
PUBLISHED WORKS
• "Significance of Endoscopically Visible Blood Vessels as an Index of Atrophic Gastritis," American Journal of Gastroenterology, 1979 • "Oral Mesalamine (Asacol) for Mildly to Moderately Active Ulcerative Colitis", Annals of Internal Medicine, Vol. 115; No. 5, 1 September 1991 • "Cisapride in the Treatment of GERD: A Double-Blind, Placebo-Controlled Multicenter Dose-Response Trial. M. DeMicco, M.D., et al., Poster Presentation AmericanGastroenterological Association. May 1992, Gastro 1992; 102: A59 • "A Double-Blind Comparison of Oral versus Rectal Mesalamine versus Combination Therapy in the Treatment of Distal Ulcerative Colitis." The Rowasa Study Group, M. Safvi, M. DeMicco, C.
Sninsky et. al., Gastroenterology 1995; 108 (A Suppl.): A909 • Sensitive Markers of Renal Dysfunction are Elevated in Chronic Ulcerative Colitis:” Asacol Study Group, C. Sninsky, S. Hanauer, B. Powers et. All.
• “A Placebo-Controlled Trial of Oral Mesalamine (Asacol) as Long Term maintenance Therapy for Ulcerative Colitis.” The Asacol Study Group, C. Sninsky, S. Hanauer, M. Robinson et. Al. Annalsof Internal Medicine, Forthcoming.
• “Maintenance of Remission of Ulcerative Colitis by Mesalamine (Asacol) vs. Placebo.”, The Asacol Study Group, S. Hanauer, B. Powers, M. Robinson et.al.
• “An Oral Preparation of Mesalamine as Long-Term Maintenance Therapy for Ulcerative Colitis: A Randomized, Placebo-Controlled Trial”, Ann Intern Med January 15, 1996 124:204-211 • Available at: http://www.annals.org/content/124/2/204.full.pdf+html?sid=210bcb7e- • “Residue-free sodium phosphate tables (OsmoPrep) versus Visicol for colon cleansing: a randomized, investigator-blinded trial”, April 2007 Gastrointestinal Endoscopy Vol. 65,Issue 4, Pages 660-670.
• “The Clinician’s Companion VI: Expert Perspectives on Contemporary Clinical Issues in Hepatitis C”, Newsletter, September 1, 2002, Tx Reporter Gastroenterology • Available at: Http://www.projectsinknowledge.com/Init/G/1571_TxReporter.pdf • "The Polymerase Inhibitor Tegobuvir (GS-9190) With Peginterferon and Ribavirin in Patients With Genotype 1 Hepatitis C." Eric J. Lawitz, Issac Bassan, Adrian Di Bisceglie, Tarek SPECIMEN
Hassanein, Maribel Rodriguez-Torres, Eliot W. Godofsky, Harvey Tatum, Graham R. Foster, IraM. Jacobson, Jean-Michel Pawlotsky, Christy Habner, Sarah Arterburn, Stven Knox, G. ManiSubramanian, John G. Hutchison, and Michael P. DeMicco.
• "Safety and Efficacy of sofosbuvir, a nucleotide polymerase inhibitor in combination, with peginterferon alfa-2a and ribavirin in treatment-naive3 patients with genotypes 1,2, and 3hepatitis C infection: a randomized, double-blind, phase 2 trail:, Authors: Eric Lawitz, MD., JayP. Lalezari, MD, Tarek Hassanein, MDKris V. Kolwdley, MD, Fred F. Poordad, MD, Aasim M.
Sheikh, MD, Neazam H. Afdhal, MD, David E. Bernstein, MD, Edwin DeJesus MD, BradleyFreilich MD, David r. Nelson MD, Douglas T. Dieterich MD., Ira M. Jacobson MD, Donald Jensen MD, Gary A. Abrams MD, Jama M. Darling MD, Maribel Rodriguez-Torres MD, K.
Rajender Reddy MD., Mark S. Sulkowski MD, Natalie H. Bzowej MD, Michael P. DeMiccoMD., James S. Strohecker MD, Robert H. Hyland, DPhuil, Hongmei Mo PhD, Ming Lin, MichaelMader, Robert Hindes MD, Effie Albanis, William T. Symonds, Pharm D, Michelle M. BerneyMD, Andrew Muir MD.
ABSTRACTS
D. Castell, C. Sigmund, D. Patterson, M. DeMicco, M. Berenson, T. Liebermann, M. Mellow, R.
Pruitt, A. Ertan, S. Faruqui, F. Lanza, D. Fitch, R. Shaker, D. Merrell, D. Hasner, C. Clyde, J.
Zeldis, “Cisapride 20 mg bid Provides Effective Daytime and Nighttime Relief in Patients withSymptoms of Chronic Gastroesophageal Reflux Disease.” AGA Abs. May 1997 Phillip P. Toskes, Frank Burton, Michael P. DeMicco, Stuart Chen, Duane Fitch, John J.
Fromkes, Michael Safdi, Z.R. Vlahcevic, “Double-Blind, randomized, Multicenter, placebo-controlled, parallel group study of the effects of oral pancreatic enzymes on steatorrhea inpatients with chronic pancreatitis.” DeMicco M., Wruble L., Medoff J, et al. Dose-ranging trial comparing 6 regimens of a newmicrocrystalline cellulose (MCC)-free formulation of sodium phosphate INKP-102 to Visicol tablets forcolon cleansing. Am J Gastroenterol 2005; 100:S348.
Sherman, R., B. Bilir, M. Sagen, Mavies, M. De Micco, S. Chandori, C. Tuthil, S. Verill, I. Rios,K. Malesk. Pilot study to evaluate the effect of the Immunomodulortes SCU-07 is a primed tosub segment response to perforated interflow/Ribariun in relapse and genotype IHCU subjects.
E.J. Lawitz, T.C. Marbury, B.D. Vince, N. Grunenberg, M. Rodriguez-Torres, M.P. DeMicco,J.N. Tarro, M.J. at all. “2008 Dose-ranging, Three-Day Monotherapy Study of the Hev Ns3Protease Inhibitor Gs-9256”, April 2010, Journal of Hepatology Vol. 52Supplement 1, pagesS466-S467.
Available at: Http://download.journals.elseviehealth.compdfs/journals/0168-8278/P11S0168827810611993.pdf E.Lawitz, M. Rodriguez-Torres, M. DeMicco, T. Nguyen, e. Godofsky, J. Appleman, M.
Rahimy, C. Croley, J. Freddo et al.,m “1055 Antiviral Activity of Ana598, A Potent Non-Nucleoside Polymerase Inhibitor, In Chronic Hepatitis C Patients:, April 2009, Journal ofHepatology Vol. 50 Supplement 1, Page S384Available at: http://download.journals.elsevierhealth.com/pdfs/journals/0168- D.R. Nelson, J. Lalezari, E.Lawitz, T. Hassanein, K.Kowdley, F.Poordad, A.Sheikh, N.Afghal,D. Bernstein, E. DeJesus, B. Freilich, D. Dieterich, I. Jacobson, D. Jensen, G.A. Abrams, J.
SPECIMEN
Darling, M. Rodriguez-Torres, R. Reddy, M. Su;lkowski, N. Bzowej, M. DeMicco, et al., “1372Once Daily Psei-7977 Plus Peg-Ifn/Rbv In Hev Gt1:98% Rapid Virologic Response, CompleteEarly Virologic Response: The Proton Study”, March 2011 Journal of Hepatology Vol.
54Supplement 1, Page S544 Available athttp://download.journals.elsevierhealth.com/pdfs/journals/0168-8278/P11S0168827811613743.pdf E. Lawitz, D. Gruener, J. Hill, T. Marbury, S. Komjathy, M. DeMicco, A. Murillo, F. Jenkin,K.Kim, J. Simpson, M. Aycock, A. Mathias, C. Yang, E. Dowdy, M. Liles, G. Cheng, E.
Mondou, J. Link, d. Brainard, J. McHutchison, C. Ohmstede, R. Bannister et al, “1219 Three- Day, Dose-Ranging Study of the Hcv Ns5a Inhibitor Gs-5885”, March 2011, Journal ofHepatology Vol. 54Supplement 1, Pages S481-S482 Available at:http://download.journals.elsevierhealth.com/pdfs/journals/0168- Richard Nettles, Xiaodong Wang, Syed Quadri, Yaoshi Wu, Min Goa, Makeonen Balema, EricLawitz, r. Goldwater, Michael P. DeMicco, et al., “1858 BMS-824393 is a Potent Hepatitis CVirus NS5A Inhibitor with Substantial Antiviral Activity when given as Monotherapy inSubjects with Chronic G1 HCV Infection”, September 6, 2010, The Liver Meeting 2010(AASLD)Available at: http://trs.scivee.tv/node/3906 SPECIMEN

Source: http://www.michaelpdemiccomd.com/DeMicco_CV_041113.pdf